Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab

類似資料

• Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
  著者:: Kim, M. M., 等
  出版事項: (2013)
• Loss of HER2 Amplification Following Trastuzumab-based Neoadjuvant Systemic Therapy and Survival Outcomes
  著者:: Mittendorf, Elizabeth A., 等
  出版事項: (2009)
• Efficacy of Neoadjuvant Therapy with Trastuzumab Concurrent with Anthracycline- and Non-anthracycline-based Regimens for HER2-Positive Breast Cancer
  著者:: Bayraktar, Soley, 等
  出版事項: (2011)
• Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
  著者:: Palmieri, Carlo, 等
  出版事項: (2015)
• Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer
  著者:: Caudle, Abigail S., 等
  出版事項: (2010)